# Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease

> **NCT00443287** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 553 (actual)

## Conditions studied

- Intermittent Claudication

## Interventions

- **DRUG:** ataciguat (HMR1766)
- **DRUG:** placebo
- **DRUG:** cilostazol

## Key facts

- **NCT ID:** NCT00443287
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 553 (ACTUAL)
- **Last updated:** 2018-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00443287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00443287, "Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00443287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*